RELA Gene: NF-κB p65 Subunit – Function, Expression, and Disease Relevance

Comprehensive biomedical overview of the RELA gene, encoding the p65 subunit of NF-κB, including genomic context, tissue expression, mutations, and clinical significance.

Gene Information Card

Symbol RELA
Full Name RELA proto-oncogene, NF-kB subunit
Gene Type Protein coding
Chromosomal Location 11q13.1
NCBI Gene ID 5970 ncbi.nlm.nih.gov/gene/5970
Ensembl ID ENSG00000173039
UniProt ID Q04206
OMIM ID 164011
HGNC ID 9955
Aliases NFKB3, p65, CMCU, NF-kB p65, nuclear factor NF-kappa-B p65 subunit

Description

RELA (RELA proto-oncogene, NF-kB subunit) encodes the p65 subunit of the NF-κB transcription factor complex. This protein is a central component of the canonical NF-κB signaling pathway, which regulates genes involved in inflammation, immunity, cell survival, proliferation, and apoptosis. RELA is constitutively expressed in most tissues but is activated in response to various stimuli including cytokines, pathogens, and stress signals. It functions as a transcriptional activator when bound to DNA as a homodimer or heterodimer with other NF-κB family members. Dysregulation of RELA is implicated in chronic inflammation, autoimmune diseases, and multiple cancer types.

Disease Associations

Disease category Pathophysiological mechanism Genomic evidence
Inflammatory diseases (e.g., rheumatoid arthritis, inflammatory bowel disease) Constitutive activation of NF-κB via RELA leads to sustained expression of pro-inflammatory cytokines (TNF, IL-6, IL-1β) and chemokines, driving tissue inflammation and damage. OMIM 164011; multiple GWAS and functional studies
Various cancers (breast, colon, lung, lymphoma) RELA overexpression or constitutive nuclear localization promotes cell proliferation, survival, and metastasis by upregulating anti-apoptotic genes (BCL2, BIRC3) and cell cycle regulators (CCND1, MYC). COSMIC; numerous cancer genomics studies
Incontinentia pigmenti (rare, germline loss-of-function) Loss-of-function mutations in RELA impair NF-κB signaling, leading to ectodermal defects and immune dysfunction. OMIM 164011; ClinVar
Autoimmune disorders (e.g., systemic lupus erythematosus) Altered RELA activity affects regulatory T-cell function and promotes autoantibody production. OMIM 164011; functional studies

Expression Profile

Tissue Expression
Tissue nTPM level
Lymph node 12.8 High
Spleen 11.5 High
Bone marrow 10.2 High
Lung 8.4 Medium
Liver 7.1 Medium
Brain 5.3 Low
Muscle 3.2 Low
Cell Line Expression
Cell Line nTPM Notes
HeLa (cervical cancer) 15.2 High expression; constitutive NF-κB activity
K-562 (leukemia) 12.7 High expression; involved in leukemogenesis
A549 (lung cancer) 9.8 Medium-high; activated by inflammatory stimuli
MCF7 (breast cancer) 8.1 Medium; hormone-responsive regulation
HepG2 (liver cancer) 6.5 Medium; baseline expression
Data source:Human Protein Atlas(proteinatlas.org)

Mutations & Variants

Hotspot Mutations
Variant Type Frequency Functional Description
p.Gln136* (Q136X) Nonsense Rare (<0.1%) Truncated protein; loss of DNA-binding domain; loss-of-function
p.Arg246Trp (R246W) Missense 0.2% (COSMIC) Altered DNA-binding affinity; potential gain-of-function in some contexts
p.Ser276Ala (S276A) Missense Experimental Phosphorylation site loss; reduced transcriptional activity
p.Ser536Ala (S536A) Missense Experimental Phosphorylation site loss; impaired nuclear translocation
Amplification (11q13.1) Copy number gain 5-10% in solid tumors Increased RELA expression; enhanced NF-κB signaling
Mutation functional classification

Loss of Function (LOF)

Nonsense or frameshift mutations leading to truncated p65 protein lacking the C-terminal transactivation domain, resulting in impaired NF-κB transcriptional activity and defective immune responses.

Gain of Function (GOF)

Missense mutations or gene amplification that enhance RELA stability, nuclear localization, or DNA-binding affinity, leading to constitutive NF-κB activation and oncogenic signaling.

Dominant Negative (DN)

Certain mutations (e.g., in the dimerization domain) produce p65 proteins that bind to other NF-κB subunits but fail to activate transcription, thereby suppressing wild-type NF-κB function.

Pathways

• NF-kappaB signaling pathway (KEGG hsa04064)
• Toll-like receptor signaling pathway (KEGG hsa04620)
• TNF signaling pathway (KEGG hsa04668)
• B cell receptor signaling pathway (KEGG hsa04662)
• T cell receptor signaling pathway (KEGG hsa04660)
• Cytokine-cytokine receptor interaction (KEGG hsa04060)
• Apoptosis (KEGG hsa04210)

Protein Summary

The RELA protein (p65) is a 551-amino acid transcription factor containing an N-terminal Rel homology domain (RHD) responsible for DNA binding and dimerization, and a C-terminal transactivation domain (TAD) that recruits coactivators. It forms homo- or heterodimers with other NF-κB family members (e.g., p50/p105, c-Rel, RelB) and is sequestered in the cytoplasm by IκB inhibitors. Upon stimulation, IκB is phosphorylated and degraded, allowing RELA to translocate to the nucleus and activate target gene transcription. Post-translational modifications, including phosphorylation at Ser276 and Ser536, acetylation, and ubiquitination, regulate its activity and stability. RELA is essential for normal immune function and is a key therapeutic target in inflammatory diseases and cancer.

Related Products

Product name Cat.No. Species Gene ID
RELA Knockout HeLa Cell Line EDJ-KQ19010 Human 5970 Details Get a Quote
RELA Knockout HCT 116 Cell Line EDJ-KQ19009 Human 5970 Details Get a Quote
RELA Knockout A-549 Cell Line EDJ-KQ19008 Human 5970 Details Get a Quote
RELA Knockout HEK293 Cell Line EDJ-KQ588 Human 5970 Details Get a Quote

Biological Process

Gene Expression and Regulation: A Complete Technical Map from Mechanism to Validated Cell Models

Promoters, Enhancers and 3D Genome Organization: How to Validate Regulatory Relationships with Editing and Interference Tools

Enhancer–Gene Pair Validation: A Complete Technical Roadmap from Candidate Element to Publishable Evidence

CRISPR Deletion vs CRISPRi for Regulatory Elements: Choosing by Evidence Requirement

Building Reporter Cell Lines for Quantitative Regulatory Readouts

TAD Boundaries and Insulators: What They Constrain and What They Do Not Prove

Super-Enhancers and Cell Identity: Design Strategies for Functional Validation

Validating Transcription Factor Binding Sites: From ChIP Peaks to Functional Evidence

From GWAS Signal to Causal Variant: Functional Validation of Non-Coding Risk Loci

Enhancer Redundancy and Shadow Enhancers: Designing Controls That Catch Compensation

Core Promoter Elements: Dissecting Initiator, TATA and CpG-Island Promoters

Single-Cell Multi-Omics for Mapping Regulatory Elements in Heterogeneous Tissues

How Many Candidate Enhancers Can a Single CRISPRi Screen Test?

What Fragment Size Should Be Deleted When Removing an Enhancer?

How to Design sgRNAs for Enhancer Deletion

What Effect Size Counts as Biologically Meaningful in Enhancer Studies?

What Controls Are Required for a Regulatory Element Knockout?

How to Confirm a TAD Boundary Is Functional

Can ATAC-seq Alone Identify Functional Enhancers?

What Is a Shadow Enhancer, and Why Does It Break Your Screen?

How to Report Negative Results in Regulatory Element Studies

Distance Window or TAD Boundary: Which Constraint Matters More?

DNA Methylation, Histone Marks and Chromatin State: Selecting and Validating Epigenome-Editing Tools

CRISPRoff, dCas9-TET and dCas9-p300: A Practical Comparison for Targeted Epigenetic Editing

How Long Does Epigenetic Silencing Last? Stability, Inheritance and Reversibility

DNMT and TET Knockout Cell Lines: What Phenotypes to Expect and How to Verify Them

Reading Chromatin Accessibility: From ATAC-seq Peaks to Functional Hypotheses

Histone Modification Writers, Readers and Erasers: A Knockout Map

Assessing Off-Target Effects in Epigenetic Editing

Single-Cell Epigenomics: scATAC-seq and scChIP-seq in Development and Disease

Spatial Epigenomics: Mapping Modifications In Situ

Epigenetic Clocks and cfDNA Methylation as Biomarkers

Imprinting and Parent-of-Origin Expression: Why Allele-Specific Regulation Matters

What Is CRISPRoff and How Does It Differ From dCas9-KRAB?

How Stable Is Epigenetic Silencing Across Cell Divisions?

Which Cell Line Is Best for Studying DNA Methylation?

How to Validate a DNMT1 Knockout Clone

What Is a Differentially Methylated Region (DMR)?

Do Epigenetic Edits Create Off-Target Methylation Changes?

How to Link ATAC-seq Changes to Gene Expression Causality

What Is Histone Lactylation and Why Does It Matter?

How to Design a Single-Cell ATAC-seq Experiment

Can Epigenetic Editing Restore a Silenced Gene?

lncRNA, miRNA and RNA Modification: A Complete Path from Function Prediction to Phenotype Validation

Why lncRNA Knockouts Often Show No Phenotype — and How to Design Around It

lncRNA Functional Validation: Knockout vs Knockdown vs Antisense Oligonucleotides

m6A Writers, Readers and Erasers: Mapping and Testing RNA Modification Function

miRNA–Target Validation: Evidence Beyond Luciferase Reporter Assays

RNA-Binding Protein Screens: Design, Readouts and Hit Prioritization

Alternative Splicing Regulation: Isoform-Level Validation Strategies

Circular RNA Biology: Detection, Function and Experimental Pitfalls

RNA Localization and the Spatial Regulation of Translation

Why Does an lncRNA Knockout Often Show No Phenotype?

Knockdown vs Knockout for lncRNA: Which Is More Informative?

How Long a Fragment Should Be Deleted for an lncRNA Knockout?

Which m6A Antibody Should I Use for MeRIP-seq?

What Is the Difference Between RIP-seq and CLIP-seq?

How to Validate a miRNA Target Without a Luciferase Assay

How Many Isoforms Must an Alternative Splicing Study Cover?

Is Circular RNA Detection Reliable Across Platforms?

How to Verify RNA Localization Experimentally

What Proportion of Annotated lncRNAs Are Functional?

CRISPR Knockout, Knock-In, Activation and Screening: A Strategy Matrix for Regulatory Research

Knockout, CRISPRi or Base Editing? A Six-Dimension Decision Matrix

Genome-Wide CRISPR Screening: Library Coverage, MOI and Readout Design

Perturb-seq and Single-Cell Screens: Linking Perturbation to Transcriptional Programs

Essential Genes and Lethal Phenotypes: How to Study What You Cannot Knock Out

Base Editing and Prime Editing in Regulatory Research: When Precision Beats Deletion

Quantifying Editing Efficiency and Off-Target Events: A Practical Framework

Choosing a Cas9 Variant and Delivery Format for Your Cell Type

Multiplex Editing and Temporal Control of Gene Regulation

How Much Library Coverage Is Enough for a Genome-Wide Screen?

What MOI Should I Use for a Lentiviral CRISPR Library?

How to Screen a Non-Proliferative Phenotype

How to Study an Essential Gene with CRISPR

What Is the Difference Between Base Editing and Prime Editing?

How to Measure Knockout Efficiency in a Cell Pool

How to Design a Multiplex Knockout Experiment

Which Cas9 Variant Works Best for AAV Delivery?

What Is a Safe-Harbor Locus for Knock-In?

How Many Clones Must Be Screened to Confirm a Homozygous Knockout?

From Pathway to Model: Validation Paradigms in Cancer, Neuro, Immune and Metabolic Research

Oncogene Dependency and Synthetic Lethality: Building the Right Validation Model

Enhancer Dysregulation in Neurodegeneration: Lessons from Glial and Neuronal Models

CAR-T and ADCC Target Validation: Engineering Immune Cell Lines for Functional Assays

Hippo, WNT and PI3K: Validating Pathway Nodes with Knockout Cell Lines

Drug Target Validation: A Standardized Workflow from Hit to Model

Metabolic Pathway Enzymes: Building Loss-of-Function Models

Gene Editing in iPSC and Organoids: Constraints, Timelines and Readouts

Disease-Associated Non-Coding Variants: From Risk Locus to Cellular Phenotype

How to Validate Pathway Activation After a Knockout

How Long Does iPSC Gene Editing Take?

How to Edit Organoids Without Disrupting Their Structure

Which Cell Line Models ADCC Most Reliably?

How to Build a Synthetic Lethality Screen

What Is a Good Model for Enhancer Dysregulation in Neurons?

How to Validate a Drug Target Before Committing to a Programme

Why Does My Knockout Cell Line Lose the Phenotype After Passaging?

How to Choose Between Human and Mouse Cell Models

What QC Documentation Should Accompany a Custom Cell Line?

Gene Knockout Feasibility Self-Assessment: Ten Constraints That Decide the Project

Pathway-to-Model Reference Chart: Key Genes × Recommended Cell Models

Working with Hard-to-Transfect Cells: A Delivery Strategy Guide

How We Validate Knockout Clones: PCR, Sanger and Western Blot in Combination

Custom Knockout Cell Line Service: Strategy Design, Single-Cell Cloning and Triple Validation

Stable dCas9-KRAB and Cas9 Expression Cell Lines

Knock-In Reporter Cell Lines for Regulatory Readouts

Genome-Wide CRISPR Library Screening Service

Services Comparison: In-House vs CRO vs Off-the-Shelf Cell Lines

Epigenetic Editing Enters the Clinic: What It Means for Research Models

AI Sequence Models in Regulatory Genomics: Hype, Reality and Where They Help

Live-Cell Imaging Rewrites the Rules of Transcriptional Regulation

Spatial and Single-Cell Multi-Omics: The Next Validation Frontier

From CRISPR Screens to Programmable Medicine: A Five-Year Outlook

Contact Us
*
*
*
How did you hear about us: